<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02256371</url>
  </required_header>
  <id_info>
    <org_study_id>P130604</org_study_id>
    <nct_id>NCT02256371</nct_id>
  </id_info>
  <brief_title>Randomized Controlled Study of the Efficacy of Hypnosis Versus Relaxation and Control in Neuropathic Pain</brief_title>
  <acronym>PSYCNEP</acronym>
  <official_title>Efficacy of 2 Psycho-physical Methods in the Treatment of Neuropathic Pain: a Randomized Controlled Monocentric Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized double-blind controlled two centers study. The primary objective of this study&#xD;
      will be to show a superiority of hypnosis over relaxation on pain intensity in patients with&#xD;
      neuropathic pain.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The secondary objectives of this study are:&#xD;
&#xD;
        -  to show a superiority of hypnosis and relaxation over control group on neuropathic pain.&#xD;
&#xD;
        -  to show a lasting effect of treatment on neuropathic pain one week after the end of&#xD;
           treatment.&#xD;
&#xD;
        -  to evaluate the clinical predictors of response to hypnosis (nature of neuropathic&#xD;
           symptoms, severity of anxiety and depressive symptoms, pain catastrophizing, coping&#xD;
           strategies, emotional regulation, response to the first session, positive or negative&#xD;
           emotional reaction at the end of hypnosis sessions).&#xD;
&#xD;
        -  to evaluate the effect of hypnosis at long-term (1, 3 and 6 months after the end of&#xD;
           treatment).&#xD;
&#xD;
        -  to evaluate the effect of hypnosis on emotional processes.&#xD;
&#xD;
        -  to compare hypnosis to relaxation on short-term effects on pain,&#xD;
&#xD;
        -  to evaluate the quality of life and the impact of pain on daily life: sleep, mood,&#xD;
           anxiety symptoms, analgesics consumption , neuropathic symptoms, affective component of&#xD;
           pain and pain catastrophizing.&#xD;
&#xD;
           35 patients will be enrolled in each arm, to obtain 105 in total (3 arms). Total&#xD;
           duration for each patient: 8 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2015</start_date>
  <completion_date type="Actual">June 22, 2021</completion_date>
  <primary_completion_date type="Actual">June 22, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Weekly mean pain intensity in patients diaries</measure>
    <time_frame>9 week</time_frame>
    <description>The pain intensity score will be recorded daily by each patient on a self-assessment diary using a scale of 0 to 10. The record will begin from the first session of hypnosis or relaxation to the last session (S1 to S9).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain intensity measured at the end of each visit and 3 and 6 months after the end of the treatment</measure>
    <time_frame>8 months</time_frame>
    <description>Pain intensity measured at the end of each hypnosis or relaxation session and 3 and 6 months after the end of the treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the feeling of comfort and relaxation</measure>
    <time_frame>9 weeks</time_frame>
    <description>At the end of each hypnosis or relaxation session, with a scale from 0 to 10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Affective components of pain</measure>
    <time_frame>8 months</time_frame>
    <description>At the end of each visit and 3 and 6 months after the end of the treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Emotional processes and Alexithymia</measure>
    <time_frame>8 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuropathic symptoms (NPSI)</measure>
    <time_frame>8 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interference with pain (Brief Pain Inventory)</measure>
    <time_frame>8 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life assessment</measure>
    <time_frame>8 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Depression and anxiety</measure>
    <time_frame>8 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Emotional distress caused by pain</measure>
    <time_frame>8 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain catastrophizing</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain relief</measure>
    <time_frame>8 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Delay of onset of analgesic effects</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of responders</measure>
    <time_frame>8 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">105</enrollment>
  <condition>Neuropathic Pain</condition>
  <arm_group>
    <arm_group_label>Hypnotic analgesia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hypnosis sessions:&#xD;
Hypnosis will consist of 45 minutes hypnosis session with a trained hypnotherapist</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Relaxation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Relaxation group:&#xD;
Relaxation will be conducted in 45 minutes sessions with a trained psychotherapist.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Routine care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The patients will receive their usual pain treatments throughout the study</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Hypnosis sessions</intervention_name>
    <description>1 session per week during 8 weeks</description>
    <arm_group_label>Hypnotic analgesia</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Relaxation group</intervention_name>
    <description>1 relaxation session per week during 8 weeks</description>
    <arm_group_label>Relaxation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  peripheral or central neuropathic pain, probable or definite&#xD;
&#xD;
          -  Diagnostic questionnaire score DN4 ≥ 4/10&#xD;
&#xD;
          -  Chronic Pain with an average of pain intensity greater than or equal to 4/10 (digital&#xD;
             scale)&#xD;
&#xD;
          -  Presence of daily or almost daily pain (i.e. at least 4 days per week)&#xD;
&#xD;
          -  Patient with pre-existing pain for &gt; 6 months&#xD;
&#xD;
          -  Patient &gt; 18 and &lt; 60 years old&#xD;
&#xD;
          -  Patient with a stable analgesic treatment since 15 days before inclusion&#xD;
&#xD;
          -  Patient able to participate to the trial during 33 weeks&#xD;
&#xD;
          -  Patient having a health insurance&#xD;
&#xD;
          -  Written informed consent signed by the patient.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior treatment with hypnosis&#xD;
&#xD;
          -  Currently under active psychotherapy (Cognitive-Behavior Therapy, psychoanalysis)&#xD;
&#xD;
          -  Work accident or litigation&#xD;
&#xD;
          -  Drugs abuse or Psychoactive Substance Abuse (DSM-IV)&#xD;
&#xD;
          -  Neuropathic pain associated with progressive disease (MS, HIV, cancer ...)&#xD;
&#xD;
          -  Major depression with ongoing disability or psychosis (DSM IV)&#xD;
&#xD;
          -  Intermittent pain&#xD;
&#xD;
          -  Patient with pre-existing pain for &lt; 6 months&#xD;
&#xD;
          -  Other more severe pain than the pain justifying inclusion&#xD;
&#xD;
          -  Subject unable to understand the trial information provided in the informed consent&#xD;
             document&#xD;
&#xD;
          -  Subject under curators or guardianship&#xD;
&#xD;
          -  Severe Handicap or amputation&#xD;
&#xD;
          -  Participation to another study in the same period&#xD;
&#xD;
          -  Deafness&#xD;
&#xD;
          -  Cognitive disorders (dementia, Mild Cognitive Impairment, inability to understand the&#xD;
             questionnaires)&#xD;
&#xD;
          -  For patients of the control arm: Treatment by hypnosis and / or relaxation,&#xD;
             transcranial magnetic stimulation, or invasive treatments (surgery)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nadine ATTAL, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Groupe Hospitalier Ambroise Paré</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre d'évaluation et de traitement de la douleur, Hôpital Ambroise Paré</name>
      <address>
        <city>Boulogne-Billancourt</city>
        <state>Hauts-de-Seine</state>
        <zip>92100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>October 1, 2014</study_first_submitted>
  <study_first_submitted_qc>October 2, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 3, 2014</study_first_posted>
  <last_update_submitted>July 19, 2021</last_update_submitted>
  <last_update_submitted_qc>July 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neuropathic pain</keyword>
  <keyword>Hypnosis</keyword>
  <keyword>Relaxation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuralgia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

